Phase 3b Study of STN1011402 ophthalmic cream in Patients With Allergic Conjunctivitis

Open-Label Crossover Study of 0.5% STN1011402 ophthalmic cream and 0.1% Epinastine hydrochloride ophthalmic solution in Patients with Allergic Conjunctivitis -phase 3b study-

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051220050

Enrollment

Registered

2022-06-16

Start date

2022-06-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Conjunctivitis

Interventions

0.5% STN1011402 ophthalmic cream (approximately 30mg/time, once a day) and 0.1% Epinastine hydrochloride ophthalmic solution (1 drop/time, twice a day) will be applied for 2 weeks at a time.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Provided signed, written informed consent. Has a positive result from a Type I allergy test.

Exclusion criteria

Exclusion criteria: Eye disease other than allergic conjunctivitis is present and requires treatment. Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception.

Design outcomes

Primary

Measure	Time frame
Usability and burden of use (Questionnaire)	—

Contacts

Public ContactSakamoto Kayoko

Santen pharmaceutical co.,ltd

clinical@santen.co.jp+81-6-4802-9341

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026